headache tirzepatide Headache: Clinical Evidence & Biomarker Insights – PlexusDx FDA approves Zepbound (tirzepatide) as

AbdallahCGJiangLDe FeyterHMFasulaMKrystalJHRothmanDLet al

Semaglutide is associated with a modest increase in gallbladder disease risk beyond that attributable to weight loss alone, with cholelithiasis reported in 1.62.5% vs 0.71.0% and cholecystitis in 0.6% vs 0.2% of Wegovy vs placebotreated adults in weightmanagement trials, and higher rates in adolescents

Dosing follows gradual escalation to minimize adverse reactions

Some experience nausea, especially early in treatment

References: Bosch C, Carriazo S, Soler MJ, Ortiz A, Fernandez-Fernandez B

Reducing oxidative stress may help prevent chronic diseases and promote overall well-being